{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"semaglutide-statins","title":"semaglutide statins","body":"## Overview\nEvidence is being populated by Grok web search.","register":"standard","hero":null,"hero_brief":"","editorial_review":null,"tags":[],"category":null,"style":{},"claims":[{"id":"c1","text":"2025 single-center before-after study (N=41) of patients with IHD on statins starting oral semaglutide for T2D showed significant reduction in RLP cholesterol (8.52 to 5.46 mg/dL, P<0.001) independent of weight loss; also reduced in subgroups on SGLT2i or switching from DPP4i.","section":"what_is_known","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Materialized from orphan source s1 by ledger repair"},{"id":"c2","text":"Case report showing oral semaglutide further lowered LDL-C in a patient already on maximal statin-based therapy plus PCSK9 inhibitor for familial hypercholesterolemia.","section":"what_is_known","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Materialized from orphan source s2 by ledger repair"},{"id":"c3","text":"Preclinical study developing and evaluating nanoparticles combining semaglutide and a statin-lipid conjugate for potential co-delivery.","section":"what_is_known","tier":"mechanistic","source_ids":["s3"],"source_status":"sourced","why_material":"Materialized from orphan source s3 by ledger repair"},{"id":"c4","text":"2025 study showing oral semaglutide further lowers remnant-like lipoprotein cholesterol in statin-treated ischemic heart disease patients.","section":"what_is_known","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Materialized from orphan source s4 by ledger repair"},{"id":"c5","text":"2025 systematic review/meta-analysis on semaglutide's CV benefits, relevant in context of statin background therapy in related trials.","section":"what_is_known","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Materialized from orphan source s5 by ledger repair"},{"id":"c6","text":"2025 review comparing CV outcomes of semaglutide (often on background statins in such populations).","section":"what_is_known","tier":"human","source_ids":["s6"],"source_status":"sourced","why_material":"Materialized from orphan source s6 by ledger repair"},{"id":"c7","text":"Case report of additional LDL-C reduction with oral semaglutide in a patient already on intensive statin-based therapy.","section":"what_is_known","tier":"human","source_ids":["s7"],"source_status":"sourced","why_material":"Materialized from orphan source s7 by ledger repair"},{"id":"c8","text":"Prespecified analysis of SOUL trial showing high baseline statin use (over 84-91%) alongside oral semaglutide in T2D patients with CV risk.","section":"what_is_known","tier":"human","source_ids":["s8"],"source_status":"sourced","why_material":"Materialized from orphan source s8 by ledger repair"},{"id":"c9","text":"Post hoc analysis of SOUL trial confirming high concomitant statin use (>80%) with oral semaglutide and effects on CV risk factors.","section":"what_is_known","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Materialized from orphan source s9 by ledger repair"},{"id":"c_map_semaglutide-statins","text":"Combinatorial mapping (transparent): semaglutide vs statins — regen=0.32, degen=0.45, Δ=-0.13. Method: layer_relevance(0.60) × evidence_factor(0.40); catalog.degen_score for Statins.","section":"what_is_known","tier":"runtime"}],"sources":[{"id":"s1","type":"medical","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11954779/","title":"Effect of oral semaglutide on remnant-like lipoprotein cholesterol in patients with ischemic heart disease receiving statin therapy","quote":"Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.","summary":"2025 single-center before-after study (N=41) of patients with IHD on statins starting oral semaglutide for T2D showed significant reduction in RLP cholesterol (8.52 to 5.46 mg/dL, P<0.001) independent of weight loss; also reduced in subgroups on SGLT2i or switching from DPP4i.","author":"","publisher":"","date":"","claim_ids":["c1"]},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40866272/","title":"Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab","quote":"We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.","summary":"Case report showing oral semaglutide further lowered LDL-C in a patient already on maximal statin-based therapy plus PCSK9 inhibitor for familial hypercholesterolemia.","author":"","publisher":"","date":"","claim_ids":["c2"]},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40284475/","title":"Preparation and Therapeutic Evaluation of Engineered Semaglutide and Statin-Lipid Conjugate Nanoparticles","quote":"The statin-lipid conjugate was successfully synthesized, forming novel nanoparticles with semaglutide in an aqueous solution.","summary":"Preclinical study developing and evaluating nanoparticles combining semaglutide and a statin-lipid conjugate for potential co-delivery.","author":"","publisher":"","date":"","claim_ids":["c3"]},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40166440/","title":"Effect of oral semaglutide on remnant-like lipoprotein cholesterol levels in patients with ischemic heart disease receiving statin therapy","quote":"Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.","summary":"2025 study showing oral semaglutide further lowers remnant-like lipoprotein cholesterol in statin-treated ischemic heart disease patients.","author":"","publisher":"","date":"","claim_ids":["c4"]},{"id":"s5","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12752371/","title":"Cardiovascular benefits of semaglutide: a systematic review and meta-analysis","quote":"This systematic review and meta-analysis demonstrates that semaglutide reduces the risk of major adverse cardiovascular events, cardiovascular mortality, and ...","summary":"2025 systematic review/meta-analysis on semaglutide's CV benefits, relevant in context of statin background therapy in related trials.","author":"","publisher":"","date":"","claim_ids":["c5"]},{"id":"s6","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12823426/","title":"Cardiovascular outcomes of semaglutide and tirzepatide for ...","quote":"Relevant for clinical practice, our findings show that treatment with semaglutide lowered the risk of MACE compared to sitagliptin, while tirzepatide showed at ...","summary":"2025 review comparing CV outcomes of semaglutide (often on background statins in such populations).","author":"","publisher":"","date":"","claim_ids":["c6"]},{"id":"s7","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13106759/","title":"Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab","quote":"We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.","summary":"Case report of additional LDL-C reduction with oral semaglutide in a patient already on intensive statin-based therapy.","author":"","publisher":"","date":"","claim_ids":["c7"]},{"id":"s8","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12144549/","title":"Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial","quote":"Concomitant use of beta-blockers (68.9% versus 62.6%), statins (91.2% versus 84.3%), and platelet aggregation inhibitors (81.2% versus 75.7%) was slightly higher in those using SGLT2i at baseline","summary":"Prespecified analysis of SOUL trial showing high baseline statin use (over 84-91%) alongside oral semaglutide in T2D patients with CV risk.","author":"","publisher":"","date":"","claim_ids":["c8"]},{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13019341/","title":"Oral Semaglutide and Change in Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial","quote":"For example, statins were used in more than 80% of enrolled participants","summary":"Post hoc analysis of SOUL trial confirming high concomitant statin use (>80%) with oral semaglutide and effects on CV risk factors.","author":"","publisher":"","date":"","claim_ids":["c9"]}],"prov":{"model":"grok/grok-4.3","action":"write"}}